🟢 Insmed is trading 4.6% up today after Cantor Fitzgerald conference highlighted stronger commercial momentum

Insmed is trading $130.63 (+4.60%) after its September 9, 2026 Cantor Fitzgerald conference highlighted stronger commercial momentum.

• Management raised its long-term outlook to $14 billion in peak sales across three commercial or late-stage products, supporting investor confidence.
• The presentation followed strong BRINSUPRI launch momentum and reinforced expectations for its pulmonary-hypertension pipeline.
• The broader market was weaker: S&P 500 down 0.50% and Nasdaq down 0.81%, making the company-specific catalyst more notable.